SecurityADMA / ADMA Biologics Inc (000899104)
President and CEOGrossman Adam S
IndustryBiological Products, Except Diagnostic Substances (Biotech)
Institutional Owners56
Institutional Shares26,061,428 - 56.23%
Common Stock Shares Outstanding46,349,514 shares (as of 2018-06-30)
Institutional Value$ 119,388,000 USD

Institutional Stock Ownership and Shareholders

ADMA Biologics Inc (NASDAQ:ADMA) has 56 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 26,061,428 shares. Largest shareholders include Perceptive Advisors Llc, Consonance Capital Management LP, Aisling Capital LLC, Broadfin Capital, LLC, Biomark Capital Management Co. LLC, Vanguard Group Inc, BlackRock Inc., 683 Capital Management, LLC, Stonepine Capital Management, LLC, and Iguana Healthcare Management, LLC.
ADMA Biologics Inc (NASDAQ:ADMA) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-08-02 13F-HR Sigma Planning Corp 18,730 0 -100.00 86 0 -100.00
2018-08-14 13F-HR TIAA CREF INVESTMENT MANAGEMENT LLC 29,011 131
2018-08-14 13F-HR HIGHBRIDGE CAPITAL MANAGEMENT LLC 312,500 0 -100.00 1,438 0 -100.00
2018-08-13 13F-HR Aisling Capital LLC 3,608,171 3,608,171 0.00 16,598 16,273 -1.96
2018-09-18 13F-HR/A NORTHERN TRUST CORP 29,143 209,313 618.23 134 944 604.48
2018-08-14 13F-HR GOLDMAN SACHS GROUP INC 93,294 0 -100.00 429 0 -100.00
2018-08-10 13F-HR Legal & General Group Plc 2,811 13
2018-08-08 13F-HR SCHWAB CHARLES INVESTMENT MANAGEMENT INC 35,400 160
2018-08-13 13F-HR Stonepine Capital Management, LLC 0 831,731 0 3,751
2018-05-15 13F-HR Iguana Healthcare Management, LLC 600,000 600,000 0.00 1,926 2,760 43.30
2018-07-11 13F-HR RAYMOND JAMES TRUST N.A. 17,792 80
2018-08-14 13F-HR Squarepoint Ops LLC 11,046 50
2018-08-14 13F-HR/A CITADEL ADVISORS LLC 12,890 0 -100.00 59 0 -100.00
2018-08-13 13F-HR Wealthcare Advisory Partners LLC 200 200 0.00 1 1 0.00
2018-08-13 13F-HR RAYMOND JAMES & ASSOCIATES 0 21,320 0 96
2018-08-14 13F-HR BARCLAYS PLC 2,901 1,388 -52.15 13 6 -53.85
2018-08-13 13F-HR Advisor Group, Inc. 300 1
2018-07-27 13F-HR Advisory Services Network, LLC 1,700 2,750 61.76 8 17 112.50
2018-08-14 13F-HR UBS Group AG 3,073 6,740 119.33 14 30 114.29
2018-08-14 13F-HR Consonance Capital Management LP 3,329,234 4,249,234 27.63 15,314 19,164 25.14
2018-09-17 13F-HR/A 683 Capital Management, LLC 805,000 885,000 9.94 3,703 3,991 7.78
2018-08-14 13F-HR TEACHERS ADVISORS INC 23,078 104
2018-08-14 13F-HR JP Morgan Chase & Co 39,491 147,996 274.76 182 667 266.48
2018-08-08 13F-HR Spark Investment Management LLC 22,200 37,460 68.74 102 168 64.71
2018-08-14 13F-HR BANK OF AMERICA CORP /DE/ 5,188 304 -94.14 24 1 -95.83
2018-08-13 13F-HR AMP Capital Investors Ltd 24,100 109
2018-08-08 13F-HR AMERICAN INTERNATIONAL GROUP INC 12,322 56
2018-08-14 13F-HR Broadfin Capital, LLC 720,529 3,249,829 351.03 3,314 14,657 342.28
2018-08-14 13F-HR MORGAN STANLEY 13,011 48,180 270.30 59 217 267.80
2018-07-24 13F-HR MEEDER ASSET MANAGEMENT INC 396 1,787
2018-08-03 13F-HR Financial Architects, Inc 15,000 68
2018-08-14 13F-HR MILLENNIUM MANAGEMENT LLC 273,621 229,416 -16.16 1,259 1,035 -17.79
2018-08-06 13F-HR STRS OHIO 5,500 24
2018-08-01 13F-HR WELLS FARGO & COMPANY/MN 8,500 10,816 27.25 39 48 23.08
2018-08-14 13F-HR VANGUARD GROUP INC 886,987 1,134,031 27.85 4,080 5,115 25.37
2018-08-09 13F-HR Biomark Capital Management Co. LLC 1,433,304 1,433,304 0.00 6,593 6,464 -1.96
2018-08-14 13F-HR STATE STREET CORP 277,005 1,249
2018-08-14 13F-HR SPRINGBOK CAPITAL MANAGEMENT, LLC 57,300 58,879 2.76 264 266 0.76
2018-07-13 13F-HR BANK OF MONTREAL /CAN/ 134 1
2018-07-27 13F-HR PIEDMONT INVESTMENT ADVISORS LLC 328 1
2018-08-10 13F-HR NEW YORK STATE COMMON RETIREMENT FUND 21,100 95
2018-08-14 13F-HR DEUTSCHE BANK AG\ 0 30,159 0 135
2018-08-09 13F-HR Private Advisor Group, LLC 52,091 235
2018-08-14 13F-HR CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM 28,946 131
2018-08-14 13F-HR PERCEPTIVE ADVISORS LLC 3,821,102 6,521,102 70.66 17,577 29,410 67.32
2018-08-06 13F-HR RHUMBLINE ADVISERS 16,060 72
2018-08-09 13F-HR BlackRock Inc. 40,536 970,839 2,295.00 186 4,378 2,253.76
2018-08-14 13F-HR MORGENS WATERFALL VINTIADIS & CO INC 300,000 375,000 25.00 1,380 1,691 22.54
2018-08-14 13F-HR BlueCrest Capital Management Ltd 23,568 0 -100.00 108 0 -100.00
2018-08-14 13F-HR Jefferies Group LLC 18,900 0 -100.00 87 0 -100.00
2017-02-10 13F-HR BlackRock Investment Management, LLC 856 856 0.00 6 4 -33.33
2018-08-14 13F-HR ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 24,100 108
2018-08-14 13F-HR ARDSLEY ADVISORY PARTNERS 80,000 361
2018-08-13 13F-HR Kepos Capital LP 107,000 483
2018-08-14 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP 94,476 0 -100.00 435 0 -100.00
2018-08-14 13F-HR GEODE CAPITAL MANAGEMENT, LLC 112,000 201,110 79.56 515 907 76.12
2018-08-13 13F-HR Ameritas Investment Partners, Inc. 1,642 7
2018-08-14 13F-HR Invesco Ltd. 46,273 209
2018-08-14 13F-HR ELEMENT CAPITAL MANAGEMENT LLC 25,663 0 -100.00 118 0 -100.00
2018-08-14 13F-HR ROYAL BANK OF CANADA 4,000 4,035 0.88 19 19 0.00
2018-07-30 13F-HR Raymond James Financial Services Advisors, Inc. 0 14,900 0 67
2018-08-10 13F-HR CITIGROUP INC 0 2,717 0 12
2017-02-10 13F-HR BlackRock Fund Advisors 18,037 18,213 0.98 131 93 -29.01
2018-08-14 13F-HR PURA VIDA INVESTMENTS, LLC 0 325,000 0 1,466

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

ADMA Biologics: Finish Line Ahead?

2018-09-06 seekingalpha
Today we will revisit ADMA Biologics, a small biotech whose stock has rallied recently to nearly $7.00 a share. (0-1)

ADMA Biologics: Buy Or Sell Before Bivigam PDUFA?

2018-08-31 seekingalpha
ADMA Biologics shares are already up 10% in less than a week since the trade was mentioned to subscribers of the premium Marketplace service. Shares have more upside ahead.

Revisiting ADMA Biologics

2018-08-24 seekingalpha
ADMA Biologics recently announced that the FDA had set an October 25, 2018, PDUFA Date for Bivigam.

Your Daily Pharma Scoop: ADMA Closer To PDUFA, Roche Proceeds, AstraZeneca Flunks

2018-07-30 seekingalpha
Discussion: ADMA Biologics (ADMA) announced that its request for amendment to BLA to relaunch BIVIGAM (intravenous immune globulin [human], 10%). PDUFA is on October 25. If the BLA is successful the product is expected to be launched in Q1 2019. Shares moved up 18% on this positive news. Following earlier FDA letters in 2014 and 2016 warning of the production facility of the drug, IVIG manufacturing facility was earlier shut down. (3-0)

ADMA Biologics: The Right Way To Fix Manufacturing

2018-06-14 seekingalpha
ADMA is in the third inning of a corporate turn-around. A manufacturing-related Warning Letter is preventing ADMA from reintroducing Bivigam to the market ($60m Revs/yr) and getting FDA approval for RI-002 (could be a $200m+/yr). While ADMA management has stated that their facility is inspection-ready, there has been a lot of uncertainty about the timing of the required FDA re-inspection and about the success of ADMA's efforts to fix the manufacturing issues. (5-5)

CUSIP: 000899104